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Abstract Caulobacter crescentus 101123 possesses a gene
(Mbl1b) encoding a metallo-L-lactamase with 32% amino acid
identity to the L1 metallo-L-lactamase from Stenotrophomonas
maltophilia. The gene was cloned into an expression vector and
the enzyme, Mbl1b, was expressed in Escherichia coli. Mbl1b
was purified. Catalytic properties for several antibiotics were
determined. The enzyme exhibits Michaelis^Menten kinetics for
imipenem, meropenem and nitrocefin but substrate inhibition
kinetics with cefoxitin, cefaloridine, penicillin G and ampicillin.
A homology model predicts Mbl1b has the same structural fold
as other metallo-L-lactamases with a detailed structure very
similar to L1 but whereas L1 is a homotetramer, Mbl1b is
monomeric. The main differences between Mbl1 and L1 are in
the N-terminal region. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
The metallo-L-lactamases are an important class of Zn2-
dependent hydrolases. They share the zinc-binding HAHAD
active site motif with a variety of other hydrolytic enzymes:
the arylsulphatases, glyoxalase II enzymes [1] and polyketide
cyclases [2]. A general picture concerning catalytic activity is
emerging of zinc acting as a Lewis acid to polarise a water
molecule or hydroxyl ion to facilitate a hydrolytic nucleophilic
attack on the carbonyl group of the substrate [3,4]. Metallo-L-
lactamases readily hydrolyse carbapenems, a relatively new
and important class of L-lactam antibiotics, to confer resis-
tance and thus are assuming increasing clinical signi¢cance.
Metallo-L-lactamases, for example IMP1 and VIM, can be
mobilised on mobile genetic elements, particularly class 1 in-
tegrons [5]. Unfortunately there are no clinically useful inhib-
itors of the metallo-L-lactamases. Bacteria, which are widely
distributed in the environment, and are opportunist patho-
gens, for example Stenotrophomonas maltophilia which causes
several diseases in immunocompromised patients, are of grow-
ing clinical concern [6]. The L1 metallo-L-lactamase from S.
maltophilia has L-lactamase activity against a wide range of
clinically useful antibiotics, including the carbapenems, con-
ferring a broad spectrum of L-lactam resistance. L1 is unique
amongst metallo-L-lactamases in that it is tetrameric [7] and
recent pre-steady-state kinetic analysis suggests that L1 uses a
mechanism that di¡ers in important details from those of
other metallo-L-lactamases [8]. Homologues to L1 are there-
fore of great interest since the sequence and kinetic di¡erences
can facilitate understanding of this interesting enzyme. An L1
homologue from Janthinobacterium lividum has previously
been described [9].
Caulobacter crescentus is a widespread Gram-negative bac-
terium found in soil and aquatic habitats [10]. Caulobacter
spp. have two distinct life-cycle stages: a motile, chemotacti-
cally active swarmer cell and a sessile stalked cell [11], and C.
crescentus is an important model system in cell di¡erentiation
studies.
This study reports the discovery of a metallo-L-lactamase
gene in the chromosome of C. crescentus (Mbl1) related to the
L1 gene of S. maltophilia, and the cloning and sequencing of
one variant, Mbl1b, and the puri¢cation and characterisation
of its L-lactamase (Mbl1b).
2. Materials and methods
2.1. Organisms and culture conditions
C. crescentus strain 101123 (Pasteur Institute Culture Collection,
Paris, France) was used in this study and was cultured aerobically
at 30‡C on Medium 28 broth or agar, as appropriate (Oxoid, Basing-
stoke, UK). Escherichia coli strains were grown aerobically at 37‡C on
Nutrient Broth or Agar (Oxoid).
2.2. Identi¢cation, TA-cloning and expression of the Mbl1 gene
The C. crescentus genome, strain CB15 [12], was searched using the
Wu-BLAST 2.0 algorithm (tBLASTn option) [13], with the known
amino acid sequence for the L1 metallo-L-lactamase from S. malto-
philia [14] as the query sequence. The Blosum62 comparison matrix
was used with gap opening and extension penalties of 10 and 0.1,
respectively.
PCR primers were selected to isolate the entire Mbl1 gene sequence.
The forward primer sequence (5P-3P) was ATGAAGCGCCT-
GATCCTGGC and the reverse primer (5P-3P) was GATCGGT-
CATCGCTTGGGCC targeting sequences at the beginning and end
of the open reading frame. PCR primers were purchased from Sigma-
Genosys (Pampisford, UK). PCR, puri¢cation and sequencing of
PCR products were performed using the methods of Avison et al.
([15]. TA cloning of the resulting amplicon into a TOPO-pTrcHis
expression vector (Invitrogen, Carlsbad, CA, USA) was carried out
as previously reported by Avison et al. [16].
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2.3. Puri¢cation of Mbl1b
Mbl1b was puri¢ed from a periplasmic preparation of an E. coli
strain transformed with Mbl1 as described for the L1 metallo-L-lac-
tamase [16]. The purity of the puri¢ed protein was assessed by electro-
spray mass spectroscopy using a VG Quattro mass spectrometer.
Samples were prepared for mass spectroscopy using the method of
Winston and Fitzgerald [17]. The concentration of puri¢ed Mbl1b was
determined from its absorbance at 280 nm using a molar extinction
coe⁄cient of 30 680 AU M31 cm31 calculated from the primary pro-
tein sequence using the Gill and von Hippel algorithm [18]. N-termi-
nal sequencing was performed on the same preparation used for mass
spectrometry using an ABI 477/120A protein sequencer.
2.4. Steady-state kinetics of antibiotic hydrolysis
The kinetic parameters kcat and Km were determined in 50 mM
cacodylate bu¡er at pH 7.0 in the presence of 100 WM Zn2 from
initial rate measurements at di¡erent substrate concentrations using
the Hanes^Woolf linearisation of the Michaelis^Menten equation [19].
Initial rates were determined by following product accumulation, at
482 nm for nitroce¢n (Becton-Dickinson, Cockeysville, MD, USA), or
substrate depletion, at 299 nm for imipenem (Merck, Sharpe and
Dohme, Huddesdon, UK) and meropenem (Zeneca Pharmaceuticals,
Maccles¢eld, UK), 233 nm for ampicillin and penicillin G, 265 nm for
cefoxitin, cefaloridine, cefmetazole and ceftazidime, and 260 nm for
cefotaxime, in an UltroSpec III spectrophotometer (Amersham Phar-
macia Biotech, Amersham, UK). Enzyme activity was also determined
in the presence of 1 WM BRL42715, a competitive inhibitor of serine
L-lactamases (Smith Kline Beecham, Harlow, UK), or 50 mM EDTA
which inhibits metallo-L-lactamases. For those antibiotics for which
substrate inhibition was seen, the initial rate data were ¢tted to a
minimal kinetic mechanism of the form:
where nSŁ represents n molecules of unproductively bound substrate,
Ki represents the inhibition constant and Kapp the apparent productive
substrate-binding constant. The phenomenological equation that was
used to represent this mechanism is
v 
EoKcat
1 S
n
Kni
0BB@
1CCA
Kapp  S WS 1
where v = the enzyme rate in WM s31, Eo = enzyme concentration (in
WM) and [S] the substrate concentration (WM). Fitting was achieved
using the non-linear least squares algorithm with the program GRA-
FIT [20].
2.5. Zinc assay
The zinc content per monomer of Mbl1 was determined by dialys-
ing a 5 WM solution of protein against 100 volumes of zinc-free 50
mM cacodylate bu¡er, pH 6.0, for 2 days with daily bu¡er changes.
The protein was then concentrated to approximately 20 WM using a
Centricon column (molecular weight cuto¡ s 10 000, Millipore Cor-
poration, Watford, UK) following the manufacturer’s instructions.
The concentrated protein was acid-hydrolysed with an equal volume
of HNO3 (BDH, Aristar grade) at 20‡C for a minimum of 24 h and
analysed with a Unicam 919 atomic absorption spectrometer at 213.9
nm.
2.6. Homology modeling of the Mbl1b enzyme
A comparative homology model of Mbl1b was created. The pri-
mary sequence of Mbl1b was threaded into the L1 single chain crystal
structure (chain A, pdb id: 1sml) using the program SWISS MODEL
[21]. The resultant molecule was energy-minimised using the program
Gromos96 [22] using parameter set 43B1 until the average absolute
derivative of coordinates with respect to energy fell below 0.01 kcal
Aî 31.
3. Results
The initial Blast search of the C. crescentus CB15 genome
(EMBL accession number AE005673) identi¢ed a 867 bp open
Fig. 1. ClustalW alignments of the L1 metallo-L-lactamase from S. maltophilia and the translation products of Mbl1 from C. crescentus CB15
(Mbl1a) and C. crescentus 101123 (Mbl1b). The arrow indicates the cleavage site for the signal peptide of precursor Mbl1 protein. The N-termi-
nal sequence of mature L1 is AEVPL.
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reading frame, Mbl1, the translated product of which is 32%
identical to the L1 L-lactamase monomer from S. maltophilia
in a ClustalW [23] alignment. A PCR reaction using genomic
DNA from C. crescentus strains 101123 produced an approx-
imate 850 bp ampli¢cation product with a nucleotide sequence
almost identical to that of strain CB15. The gene product,
Mbl1b, di¡ers from that of CB15 by six amino acids. Fig. 1
shows the alignment of these two C. crescentus protein se-
quences with L1.
The PCR product was TA-cloned into TOPO-pTrcHis and
the gene resequenced to check that the desired clone had been
recovered. The cloned gene was 100% homologous to that of
C. crescentus 101123.
Puri¢cation of the protein expressed from the cloned am-
plicon of strain 101123 yielded a gel ¢ltration peak corre-
sponding to a protein of molecular weight 29 kDa. Mass
spectrometry of this protein showed a single peak of molec-
ular mass 28 790 þ 50 with an N-terminal sequence of
DDMPAN, consistent with the mature protein starting at res-
idue 22 (see arrow in Fig. 1). The predicted mass of the ma-
ture product (assuming the mature protein starts at D22) is
28 744.
The puri¢ed protein contained 1.87 þ 0.3 mol of zinc per
mol of protein. This protein showed good L-lactamase activity
against nitroce¢n that was completely abolished by incubation
with 50 mM EDTA, but was insensitive to BRL47215. The
steady-state kinetic parameters for the enzyme against several
di¡erent types of L-lactam are shown in Table 1. The enzyme
shows conventional Michaelis^Menten kinetics with imipe-
nem, meropenem and nitroce¢n as substrate (Fig. 2a). How-
ever, with cefoxitin, cefaloridine, penicillin G and ampicillin
substrate inhibition was seen (Fig. 2b).
During the creation of the homology model of Mbl1b, the
preliminary threading produced a remarkable ¢t. With the
exception of residues E56, R57 and N58 the RMS deviation
of the K carbon chain of Mbl1b from that of L1 was 6 0.76
Aî , even prior to energy minimisation. The ¢nal model clearly
demonstrated the KLLK fold typical of other metallo-L-lac-
tamases and all the putative active site residues of Mbl1b
are predicted to be in identical orientations to those in the
L1 reference structure (Fig. 3). A copy of the pdb ¢le of the
model is available by e-mail from the corresponding author.
4. Discussion
The activity of puri¢ed Mbl1b was tested against all L-lac-
tams and the strong similarity of the homology model to the
L1 crystal structure clearly indicates that Mbl1b is a metallo-
L-lactamase. The presence of a signal peptide in the primary
translation product indicates that the enzyme is normally peri-
plasmic, a prediction subsequently con¢rmed in E. coli. The
principal di¡erence between the L1 sequence and that of Mbl1
lies in the N-terminal region. In L1 the ¢rst 16 N-terminal
amino acids form an extension relative to other metallo-L-
lactamases. Extensions of the A and C (and B/D) L1 subunits
interact via residues L5, L8 and Y11. Mbl1 lacks this region.
Table 1
Mbl1b kinetic parameters for several L-lactams
Antibiotic Kam (WM) kcat (s
31) kcat/Km (WM31 s31) Ki (WM) n
Imipenem 200 (90) 940 (65) 4.7 (0.73) ^ ^
Meropenem 330 (250) 650 (44) 1.97 (2.8) ^ ^
Cefoxitin 130 (2) 1300 (1.1) 10 (0.55) 260 7
Cefaloridine 580 (300) 950 (28) 1.64 (0.09) 260 8
Ceftazidime 5000 (145) 260 (27) 0.05 (0.2) 100 4
Nitroce¢n 96 (7) 1800 (20) 18.8 (2.9) ^ ^
Penicillin G 20 (50) 770 (1100) 38.5 (22) 880 4
Ampicillin 84 (40) 57 (175) 0.68 (4.4) 910 3
Comparable ¢gures for L1 (taken from [25] or [26]) are in parentheses. n is the value required to ¢t the observed kinetics to Eq. 1. Kinetic esti-
mates were the result of three replicates and standard errors were less than 10% of mean values. The enzyme concentration used in the assay
was 0.01 WM except for nitroce¢n and imipenem where 0.005 WM was used and ceftazidime for which the concentration was 0.05 WM.
aFor those substrates for which substrate inhibition was observed, Kapp is reported rather than Km.
Fig. 2. Rate v. substrate concentration pro¢les for meropenem and
cefaloridine. Rate: WM s31, Substrate: WM. a: Data for meropenem
for which the ¢tted curve is a Michaelis^Menten equation using ki-
netic parameters from Table 1. b: Data for cefaloridine showing
substrate inhibition for which the ¢tted curve is Eq. 1 with kinetic
parameters from Table 1.
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In addition to the crystal structure, Ullah et al. [7] presented
models of ampicillin, ceftazidime and imipenem bound to the
active site of the L1 metallo-L-lactamase. For each L-lactam
the N-terminal extensions were important for binding the
antibiotic. In particular, hydrophobic interactions between
Y11 and aromatic groups on the various L-lactams were iden-
ti¢ed as factors that may stabilise transition states. The kinetic
data for Mbl1b are broadly consistent with this model of
metallo-L-lactamase mechanism, in that for all of the L-lac-
tams tested (with the exception of penicillin G) the Kapp (or
Km) was signi¢cantly greater than that for L1. Interestingly,
kcat/Km values are also greater than those for L1 in ¢ve out of
eight cases, suggesting that once the L-lactam substrate mol-
ecule is productively bound to the active site, hydrolysis in
these cases is more e⁄cient than with L1.
Substrate inhibition of Mbl1b by some but not other L-
lactams is a new ¢nding for metallo-L-lactamases. The exact
mechanism of substrate inhibition is unknown but was seen
with all penicillins and most cephalosporins tested (the excep-
tion being nitroce¢n). The carbapenems tested showed con-
ventional Michaelis^Menten kinetics. These ¢ndings imply
that the di¡erent kinetics have a fundamental structural basis
and that di¡erent antibiotics may have di¡erent mechanisms
of hydrolysis. The principal di¡erence between the carbape-
nems and other L-lactams is that both penicillins and cepha-
losporins have bulky aromatic ring substitutions which the
¢rst lack. The active sites of metallo-L-lactamases are shallow
open grooves lined with hydrophobic groups and, from the
homology model, Mbl1b is similar. We speculate that the
value of n in Table 1 may be a function of the number of
unproductive conformations of these bulky substitutions.
In the L1 crystal structure, tryptophan 17 helps stabilise the
zinc ligand histidine 225 via edge^face contacts. In Mbl1 this
tryptophan (W7) is conserved in Mbl1b. All the other active
site ligands identi¢ed in L1 are present and their orientations
in the homology model are almost identical to those in L1
(Fig. 3). Given this, as expected, the protein binds two zinc
ions per subunit.
L1 is unique amongst metallo-L-lactamases in that it is
tetrameric; the others are monomeric [3]. One of the principal
residues involved in L1 inter-chain stabilisation is Met140,
which interacts with a hydrophobic pocket on the adjacent
subunit (A/D, and B/C). An equivalent methionine is absent
from the Mbl1b sequence and, as expected, Mbl1 is mono-
meric. These di¡erences between Mbl1 and L1 suggest that
Mbl1 is likely to be of considerable use as a model system for
elucidating the detailed mechanism of the metallo-L-lactam-
ases, serving as a link between the monomeric enzyme and the
tetramer, L1.
The biological role of the Mbl1 L-lactamase in C. crescentus
is uncertain. Strain 101123 was isolated before antibiotics
were administered to farm animals [24] and comes from an
environment in which signi¢cant exposure to L-lactams is un-
likely. However, it is possible that the organism has experi-
enced su⁄ciently persistent selective pressure due to natural
environmental L-lactams, for example from fungi. Stalked
bacteria have been observed attached to trichomycetous fungi
in the hindgut of soil-inhabiting millipedes. Caulobacter spp.
can be isolated readily both from soil samples and from such
hindgut fungal samples [10]. It is quite possible that this pro-
tein represents an ancestral hydrolase that has been selected to
counteract the e¡ect of naturally occurring fungal L-lactams
in the normal environment of the bacteria.
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